In this article, we will list the 5 Small–Cap Stocks Insiders Are Buying Recently. Please visit 10 Small–Cap Stocks Insiders Are Buying Recently if you would like to see the extended list and the methodology behind it.
5. Strive Asset Management, LLC (NASDAQ:ASST)
On March 23, 2026, Maxim lowered the price target on Strive Asset Management, LLC (NASDAQ:ASST) to $20 from $30 and maintained a Buy rating. Maxim said the stock remains a Bitcoin accumulation story with a strengthened balance sheet and differentiated access to capital, but reduced its target to reflect a lower assumed Bitcoin value of $100,000 versus $150,000 previously.
On March 19, 2026, Strive Asset Management, LLC (NASDAQ:ASST) reported adjusted EPS since listing of ($4.73) and revenue of $1.5M, while accumulating 13,628 bitcoin as of March 17, 2026. CEO Matthew Cole said the company is focused on digital credit as a “multi-trillion dollar opportunity,” highlighting its SATA product as a “liquid and scalable solution” aimed at delivering yield with limited volatility, while maintaining a strong balance sheet.
Earlier in March, B. Riley analyst Fedor Shabalin initiated coverage with a Buy rating and a $12 price target, describing the company’s model as “compelling” with a combination of bitcoin treasury and asset management, and pointing to its capital structure and valuation discount.
Strive Asset Management, LLC (NASDAQ:ASST) operates as an investment manager providing portfolio management services.
4. Grocery Outlet Holding Corp. (NASDAQ:GO)
On March 25, 2026, Grocery Outlet Holding Corp. (NASDAQ:GO) disclosed in a regulatory filing that CEO Jason Potter purchased 112.8K shares of common stock on March 23 in a transaction valued at $717.2K.
On March 9, 2026, BofA lowered its price target on Grocery Outlet Holding Corp. (NASDAQ:GO) to $10.50 from $13 and maintained a Neutral rating, citing ongoing supply chain pressure and affordability challenges for core consumers, along with uncertain timing for recovery in comparable sales and basket size. DA Davidson also lowered its price target to $7 from $11 and kept a Neutral rating following a Q4 earnings miss and below-consensus guidance, noting that business trends weakened mid-year and continued to deteriorate into year-end and early 2026, while pointing to store closures and other initiatives aimed at stabilizing performance.
Earlier in March, Grocery Outlet Holding Corp. (NASDAQ:GO) reported Q4 adjusted EPS of 19c, below the 21c consensus estimate, with revenue of $1.22B compared to $1.23B consensus, while comparable store sales declined 0.8%. CEO Jason Potter said the company has “more work to do,” citing intensified consumer pressure and increased promotional activity, and added that efforts are underway to improve value perception, refresh stores, and close underperforming locations to strengthen results.
Grocery Outlet Holding Corp. (NASDAQ:GO) operates a network of retail stores offering consumables and fresh products in the United States.
3. Larimar Therapeutics, Inc. (NASDAQ:LRMR)
On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush said the Q4 update was in line with expectations as the company prepares for its nomlabofusp regulatory submission in June 2026, noting management reiterated a cash runway into Q2 2027 following recent financing, while near-term focus is on updated open-label data expected in Q2.
On March 19, 2026, Larimar Therapeutics, Inc. (NASDAQ:LRMR) reported Q4 EPS of (73c), compared to the (55c) consensus estimate. As of December 31, 2025, the company had $136.9M in cash, cash equivalents, and marketable securities, along with $107.6M in net proceeds from a February 2026 public offering, supporting a projected cash runway into Q2 2027. Chief Executive Officer Carole Ben-Maimon said the company is advancing nomlabofusp toward registration, highlighting “Breakthrough Therapy Designation” and ongoing FDA engagement, while noting plans to submit a Biologics License Application in June 2026 and report topline data from an open-label study in Q2.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) develops treatments for rare diseases using its cell-penetrating peptide technology platform.
2. Thryv Holdings, Inc. (NASDAQ:THRY)
On March 24, 2026, Thryv Holdings, Inc. (NASDAQ:THRY) announced the launch of Thryv AI Lead Flow, an end-to-end solution that integrates online visibility, lead management, and automated sales follow-ups into a single platform designed to require no manual effort once implemented.
Last month, B. Riley analyst Zach Cummins lowered the price target on Thryv Holdings, Inc. (NASDAQ:THRY) to $5 from $15 and maintained a Buy rating, citing FY26 guidance that disappointed following a strategic shift toward an AI-native unified SaaS platform. Zach Cummins noted the change led to a 46% decline in the share price and said management expects near-term churn from smaller customers in the first half of 2026, with growth from higher-value clients supporting a return to growth and free cash flow expansion in the second half.
Thryv Holdings, Inc. (NASDAQ:THRY) reported revenue of $191.62M versus the $191.26M consensus. CEO Joe Walsh said the company delivered “solid” results with 34% SaaS revenue growth and a 16.0% adjusted EBITDA margin, while highlighting the transition toward a software-focused model and a shift to an AI-enabled unified platform.
Thryv Holdings, Inc. (NASDAQ:THRY) provides digital marketing and cloud-based software solutions for small and medium-sized businesses.
1. Mission Produce, Inc. (NASDAQ:AVO)
On March 19, 2026, Freedom Capital initiated coverage of Mission Produce, Inc. (NASDAQ:AVO) with a Buy rating and a $15 price target. Freedom Capital said the company is a global sourcing, production, and distribution business focused on Hass avocados, noting that global consumption continues to grow amid demand for healthy and fresh foods.
On March 12, 2026, Mission Produce, Inc. (NASDAQ:AVO) reported Q1 adjusted EPS of 10c, above the 7c consensus estimate, with revenue of $278.6M compared to the $260.73M consensus. CEO Steve Barnard said the company is off to a “strong start,” highlighting 14% volume growth and margin expansion driven by normalized pricing and operational execution, while emphasizing focus on volume growth and per-unit margin.
Mission Produce, Inc. (NASDAQ:AVO) expects FY26 capital expenditures of $40M, and President John Pawlowski said the pending Calavo Growers acquisition could deliver “at least $25 million” in annual synergies, with the transaction expected to close in the fiscal third quarter.
Mission Produce, Inc. (NASDAQ:AVO) sources, produces, and distributes avocados and other fruits globally.
While we acknowledge the potential of AVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVO and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Must-Buy Real Estate Stocks to Invest In and 11 Best High Volume Penny Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
